Abstract
Mutations that activate the small GTP-binding protein KRAS are the most common oncogenic event in human tumors. Thirty years after its discovery, mutant KRAS has yet to be therapeutically conquered.
Original language | English |
---|---|
Pages (from-to) | 19-21 |
Number of pages | 3 |
Journal | Cancer Discovery |
Volume | 4 |
Issue number | 1 |
DOIs | |
Publication status | Published - Jan 2014 |
ASJC Scopus subject areas
- Oncology